Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials

Int Forum Allergy Rhinol. 2022 Sep;12(9):1191-1195. doi: 10.1002/alr.22964. Epub 2022 Jan 31.
No abstract available

Keywords: biomarker; chronic rhinosinusitis; eosinophilic rhinitis and nasal polyposis; paranasal sinus diseases; therapeutics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Chronic Disease
  • Clinical Trials, Phase III as Topic
  • Humans
  • Inflammation
  • Nasal Polyps*
  • Rhinitis*
  • Sinusitis*


  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • dupilumab

Associated data

  • ClinicalTrials.gov/NCT02912468
  • ClinicalTrials.gov/NCT02898454